Date: 2017-03-16
Type of information: Research agreement
Compound: allosteric modulators of the epigenetic protein LSD1
Company: Beactica (Sweden) Uppsala University (Sweden) SciLifeLab (Sweden)
Therapeutic area: Cancer - Oncology
Type agreement: research - R&D
Action mechanism: allosteric modulators of the epigenetic protein LSD1
Disease: glioma
Details:
- • On May 16, 2017, Beactica, a Swedish drug discovery company, announced a new research collaboration with Uppsala University and the Drug Discovery and Development Platform at SciLifeLab to study the effects on brain cancer stem cells of specific small molecules under development by Beactica.
- The goal of the collaboration is to evaluate and characterize the pre-clinical efficacy of Beactica’s allosteric modulators of the epigenetic protein LSD1 in glioma-inducing cells. The collaboration will also evaluate Beactica’s compounds in combination with multiple other anti-cancer agents.
- Professor Bengt Westermark and Dr Anna Segerman at Uppsala University’s Faculty of Medicine, have developed a unique capability to study glioma-initiating stem cells. Their cell clones are established from fresh biopsies and characterized with regards to genotype, phenotype and treatment response including standard treatment of care for glioblastoma. The methodology and background research is described in Cell Reports.
- The Beactica study will be performed at the In Vitro and Systems Pharmacology Facility of SciLifeLab Drug Discovery and Development Platform.
Financial terms:
Latest news:
Is general: Yes
